肺動脈性肺高血圧症(Pulmonary Arterial Hypertension):治療薬開発パイプライン動向(2015年上半期版)...市場調査レポートについてご紹介

【英文タイトル】Pulmonary Arterial Hypertension - Pipeline Review, H1 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pulmonary Arterial Hypertension Overview 8
Therapeutics Development 9
Pipeline Products for Pulmonary Arterial Hypertension – Overview 9
Pipeline Products for Pulmonary Arterial Hypertension – Comparative Analysis 10
Pulmonary Arterial Hypertension – Therapeutics under Development by Companies 11
Pulmonary Arterial Hypertension – Therapeutics under Investigation by Universities/Institutes 15
Pulmonary Arterial Hypertension – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pulmonary Arterial Hypertension – Products under Development by Companies 19
Pulmonary Arterial Hypertension – Products under Investigation by Universities/Institutes 23
Pulmonary Arterial Hypertension – Companies Involved in Therapeutics Development 24
Actelion Ltd 24
APT Therapeutics, Inc. 25
Arena Pharmaceuticals, Inc. 26
Asahi Kasei Pharma Corp. 27
Ascendis Pharma A/S 28
Bial – Portela & Ca, S.A. 29
Cardioxyl Pharmaceuticals, Inc. 30
Carolus Therapeutics, Inc. 31
Celladon Corporation 32
Celsion Corporation 33
Corridor Pharmaceuticals Inc. 34
Cytokinetics, Inc. 35
Eli Lilly and Company 36
Gilead Sciences, Inc. 37
HanAll Biopharma Co., Ltd. 38
Insmed Incorporated 39
Ironwood Pharmaceuticals, Inc. 40
Lacer, S.A. 41
Longevity Biotech, Inc 42
LTT Bio-Pharma Co., Ltd. 43
Mast Therapeutics, Inc. 44
Mezzion Pharma Co. Ltd. 45
miRagen Therapeutics, Inc. 46
Nippon Shinyaku Co., Ltd. 47
Novartis AG 48
PharmaIN Corporation 49
PhaseBio Pharmaceuticals, Inc. 50
Pluristem Therapeutics Inc. 51
Proteo, Inc. 52
Reata Pharmaceuticals, Inc. 53
Sagene Pharmaceuticals, Inc. 54
Silence Therapeutics plc 55
Sinoxa Pharma GmbH 56
Suda Ltd 57
Therametrics holding AG 58
Toray Industries, Inc. 59
United Therapeutics Corporation 60
Pulmonary Arterial Hypertension – Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 66
Assessment by Route of Administration 69
Assessment by Molecule Type 71
Drug Profiles 73
(allopurinol + apocynin) – Drug Profile 73
(chlorthalidone + valsartan) – Drug Profile 74
ACP-009 – Drug Profile 75
Antibody for Cancer and PAH – Drug Profile 76
Antibody for Pulmonary Arterial Hypertension – Drug Profile 77
APT-102 – Drug Profile 78
bardoxolone methyl – Drug Profile 80
beraprost sodium nanoparticles SR – Drug Profile 83
beraprost sodium SR – Drug Profile 84
BIA-51058 – Drug Profile 86
bosentan CR – Drug Profile 87
CT-2009 – Drug Profile 88
DasKloster-1000-01 – Drug Profile 89
Elafin – Drug Profile 91
esuberaprost sodium – Drug Profile 94
fasudil – Drug Profile 95
GS-4997 – Drug Profile 96
imatinib mesylate – Drug Profile 97
IW-1973 – Drug Profile 99
LA-419 – Drug Profile 100
lisuride – Drug Profile 101
macitentan – Drug Profile 103
Mydicar – Drug Profile 106
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension – Drug Profile 108
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension – Drug Profile 109
PB-1046 – Drug Profile 110
PB-1120 – Drug Profile 112
Peptide to Antagonize Urotensin-II Receptor for PAH – Drug Profile 113
PGC-VIP – Drug Profile 114
PK-10453 – Drug Profile 115
R-190 – Drug Profile 116
ralinepag – Drug Profile 118
RNAi Oligonucleotide to Inhibit miR-145 for PAH – Drug Profile 120
selegiline + PDE-5 Inhibitor – Drug Profile 121
selexipag – Drug Profile 122
Small Molecule for Pulmonary Arterial Hypertension – Drug Profile 124
Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia – Drug Profile 125
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction – Drug Profile 126
Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension – Drug Profile 127
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension – Drug Profile 128
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension – Drug Profile 129
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension – Drug Profile 130
sodium nitrite – Drug Profile 131
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 133
SUD-004 – Drug Profile 135
Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension – Drug Profile 136
tadalafil – Drug Profile 137
TPN-171 – Drug Profile 139
treprostinil diolamine – Drug Profile 140
TXA-127 – Drug Profile 141
udenafil – Drug Profile 143
Pulmonary Arterial Hypertension – Recent Pipeline Updates 145
Pulmonary Arterial Hypertension – Dormant Projects 168
Pulmonary Arterial Hypertension – Discontinued Products 169
Pulmonary Arterial Hypertension – Product Development Milestones 170
Featured News & Press Releases 170
Appendix 176
Methodology 176
Coverage 176
Secondary Research 176
Primary Research 176
Expert Panel Validation 176
Contact Us 176
Disclaimer 177


【レポート販売概要】

■ タイトル:肺動脈性肺高血圧症(Pulmonary Arterial Hypertension):治療薬開発パイプライン動向(2015年上半期版)
■ 英文:Pulmonary Arterial Hypertension - Pipeline Review, H1 2015
■ 発行日:2015年3月19日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6252IDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。